Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Smallpox vaccine provides more protection than previously thought

26.05.2003


Researchers at Oregon Health & Science University this week announced preliminary study results showing smallpox vaccine protection lasts longer than previously thought. Until now, it was widely accepted that smallpox vaccine protection lasted approximately three to five years. However, early study data shows that significant, partial protection may last many decades after inoculation.



“More than 90 percent of Americans older than 35 have already been vaccinated against smallpox. This translates into about 150 million people who are likely to have at least some level of detectable immunity against this disease,” said Mark Slifka, Ph.D., a researcher at the OHSU Vaccine and Gene Therapy Institute. Slifka and his colleague Erika Hammarlund presented the initial findings at this week’s meeting of the American Society for Microbiology in Washington, D.C.

To conduct their research, Slifka and his colleagues studied blood samples taken from 306 people who had received smallpox vaccinations. These immunizations occurred as recently as one month prior to testing and as long ago as 75 years. Scientists concentrated on two types of immunity in these patients. The first form of immunity is linked to levels of antibody produced in the body in response to the vaccine. These antibodies protect patients by forming the first line of defense against smallpox if an exposure occurs. The second form of immunity is T-cells programmed by the vaccine to attack the smallpox virus.


“What we found was that while T-cell immunity declines slowly over time, antibody immunity can last throughout a person’s life,” said Slifka. “Remarkably, we were able to identify some types of virus-specific immunity in volunteers who were vaccinated up to 75 years ago, indicating that their immune systems remembered the virus for three-fourths of a century after smallpox vaccination. These results are likely to have a profound impact on current models and theories on how rapidly smallpox would spread in contemporary populations because immunity following smallpox vaccination is lasting much longer than people expected.”

However, Slifka believes the pre-event vaccination of first-responders, the military, or members of smallpox task force teams remains necessary. “People with a potential occupational risk for exposure to smallpox should still be vaccinated as a safety precaution” he said. “Likewise, in the event of a smallpox outbreak, those who have come into contact with smallpox victims should be vaccinated or revaccinated as a fundamental safeguard against contracting the disease, and this serves as an important measure against spreading smallpox to others.”

Another important finding of the study was that people who had received vaccinations several times in the past had essentially the same immunity level as those vaccinated once or twice. Researchers believe immunizations create a short-term burst of higher immunity that, over time, appears to return to a set point no matter how many times a person has been vaccinated.

The smallpox vaccine’s active ingredient is a virus called vaccinia, that is closely related to smallpox. However, unlike smallpox, vaccinia does not cause serious health problems in most patients. The virus promotes smallpox protection by causing the body to produce protective antibodies and white blood cells that can search for and destroy smallpox-infected cells.

Future studies in the Slifka lab will focus on determining the level of immunity that could be considered protective in the case of an outbreak. This information would help health officials determine which members of the previously vaccinated population are at highest risk. It would also guide emergency health providers in making decisions about vaccination priorities.

“This research helps illustrate how world events have refocused scientific research and resources to better respond to major health threats that could have devastating effects,” added Jay Nelson, Ph.D., director of the Vaccine and Gene Therapy Institute. “OHSU has proposed a number of initiatives to aid in this national effort.”

Slifka and many of his colleagues are part of the newly formed Pacific Rim Biodefense Center (PRBC). The PRBC is a collaborative effort headed by OHSU. Member institutions will investigate new ways to fight infectious diseases – spread through natural causes or bioterrorism – that threaten human health. The PRBC includes the University of Hawaii at Manoa; the University of Nevada, Reno; Oregon State University; the University of Idaho; Princeton University; and Pacific Northwest National Laboratory (PNNL).

In addition to the PRBC, OHSU has proposed expansion of research and facilities aimed at developing vaccines to combat infectious disease. More information about this effort, called the Pacific Rim Vaccine Initiative, can be found at www.ohsu.edu/prvi.

Jim Newman | EurekAlert!
Further information:
http://www.ohsu.edu/
http://www.ohsu.edu/prvi

More articles from Health and Medicine:

nachricht Satellites, airport visibility readings shed light on troops' exposure to air pollution
09.12.2016 | Veterans Affairs Research Communications

nachricht Oxygen can wake up dormant bacteria for antibiotic attacks
08.12.2016 | Penn State

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Electron highway inside crystal

Physicists of the University of Würzburg have made an astonishing discovery in a specific type of topological insulators. The effect is due to the structure of the materials used. The researchers have now published their work in the journal Science.

Topological insulators are currently the hot topic in physics according to the newspaper Neue Zürcher Zeitung. Only a few weeks ago, their importance was...

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Researchers identify potentially druggable mutant p53 proteins that promote cancer growth

09.12.2016 | Life Sciences

Scientists produce a new roadmap for guiding development & conservation in the Amazon

09.12.2016 | Ecology, The Environment and Conservation

Satellites, airport visibility readings shed light on troops' exposure to air pollution

09.12.2016 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>